CIK 0001439725 · Non-accelerated filer<br>Smaller reporting company
BIODESIX INC
Sign in to watch- Ticker
- BDSX
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 203986492
- Phone
- 303-417-0500
- Business address
- 919 WEST DILLON ROAD, LOUISVILLE, CO, 80027
- Open-market buys, last 90 days
- $1,001,990
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$1,001,990. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-31 | PATIENCE JOHN Director | Option exercise | +46,686 | 384,612 | ||
| 2025-03-31 | PATIENCE JOHN Director | Option exercise · Restricted Stock Units | −46,686 | 0 | ||
| 2025-02-20 | Vazquez Chris Chief Accounting Officer | Grant or award · Restricted Stock Units | +45,050 | 45,050 | ||
| 2025-02-20 | Vazquez Chris Chief Accounting Officer | Grant or award · Stock Options (Right to buy) | +90,100 | 90,100 | ||
| 2025-02-20 | Vazquez Chris Chief Accounting Officer | Grant or award · Stock Options (Right to buy) | +39,664 | 39,664 | ||
| 2025-02-20 | Pestano Gary Anthony Chief Development Officer | Grant or award · Restricted Stock Units | +122,200 | 122,200 | ||
| 2025-02-20 | Pestano Gary Anthony Chief Development Officer | Grant or award · Stock Options (Right to buy) | +244,400 | 244,400 | ||
| 2025-02-20 | Pestano Gary Anthony Chief Development Officer | Grant or award · Stock Options (Right to buy) | +3,810 | 3,810 | ||
| 2025-02-20 | O'Kane Kieran Chief Commercial Officer | Grant or award · Restricted Stock Units | +117,500 | 117,500 | ||
| 2025-02-20 | O'Kane Kieran Chief Commercial Officer | Grant or award · Stock Options (Right to buy) | +235,000 | 235,000 | ||
| 2025-02-20 | O'Kane Kieran Chief Commercial Officer | Grant or award · Stock Options (Right to buy) | +87,319 | 87,319 | ||
| 2025-02-20 | Hutton Scott President & CEO | Grant or award · Restricted Stock Units | +387,500 | 387,500 | ||
| 2025-02-20 | Hutton Scott President & CEO | Grant or award · Stock Options (Right to buy) | +775,000 | 775,000 | ||
| 2025-02-20 | Hutton Scott President & CEO | Grant or award · Stock Options (Right to buy) | +425,929 | 425,929 | ||
| 2025-02-20 | Cowie Robin Harper CFO, Sec'y & Treasurer | Grant or award · Restricted Stock Units | +117,500 | 117,500 | ||
| 2025-02-20 | Cowie Robin Harper CFO, Sec'y & Treasurer | Grant or award · Stock Options (Right to buy) | +235,000 | 235,000 | ||
| 2025-02-20 | Cowie Robin Harper CFO, Sec'y & Treasurer | Grant or award · Stock Options (Right to buy) | +73,398 | 73,398 | ||
| 2025-02-11 | Vazquez Chris Chief Accounting Officer | Sale | −3,630 | $0.92 | $3K | 17,623 |
| 2025-02-11 | Pestano Gary Anthony Chief Development Officer | Sale | −16,748 | $0.92 | $15K | 156,008 |
| 2025-02-11 | O'Kane Kieran Chief Commercial Officer | Sale | −17,527 | $0.92 | $16K | 128,039 |
Page 9 of 14 · 274 trades